On the BSE, 2,235 shares were traded in the counter so far compared with average daily volumes of 1,743 shares in the past two weeks. The stock had hit a high of Rs 552.95 and a low of Rs 545.30 so far during the day. The stock hit a 52-week high of Rs 784.80 on 9 January 2018. The stock hit a 52-week low of Rs 456.25 on 24 May 2017.
Aarti Drugs announced that one of its units has been adversely affected due to massive explosion in adjoining Unit E - 107 of Novaphene Specialties situated at Maharashtra Industrial Development Corporation (MIDC), Tarapur. The assessment of damages is under process. The aforesaid unit contributed 16% of total revenue from operations of the company for the period ended 31 December 2017.
On a consolidated basis, net profit of Aarti Drugs rose 30.70% to Rs 23.33 crore on 15.79% rise in net sales to Rs 335.41 crore in Q3 December 2017 over Q3 December 2016.
Aarti Drugs is a pharmaceutical company. The company has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups. With its manufacturing facilities at Tarapur and Sarigam, the company manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors, besides its range in anti-diabetic, anti-cholinergic, sedatives and anti-depressant drugs.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)